MGST2 Antibody

What is MGST2 and why is it important for research?

MGST2 (Microsomal glutathione S-transferase 2) is a 147 amino acid protein belonging to the MAPEG (Membrane Associated Proteins in Eicosanoid and Glutathione metabolism) family. It plays a critical role in producing leukotriene C4 (LTC4) from leukotriene A4 (LTA4) and reduced glutathione . MGST2 functions as an intracrine mediator of cell death signaled by endoplasmic reticulum stress and oxidative DNA damage induced by common chemotherapeutic agents . Additionally, it exhibits GSH-dependent lipid peroxidase activity .

MGST2 is predominantly expressed in liver, spleen, skeletal muscle, heart, adrenals, pancreas, prostate, testis, fetal liver, and fetal spleen, with very low expression in lung, brain, placenta, and bone marrow . It is the only GST expressed in human umbilical vein endothelial cells (HUVECs) . Studying MGST2 is valuable for understanding cellular responses to oxidative stress and developing therapeutic strategies for inflammatory and metabolic disorders.

Which applications are MGST2 antibodies suitable for?

Based on available research data, MGST2 antibodies have been validated for several applications:

When selecting an antibody for a specific application, researchers should review the validation data provided by manufacturers. For example, the MGST2 polyclonal antibody (CAB16400) has been specifically validated for detecting the ~17kDa MGST2 protein in Western blotting applications using U-937 and PC-12 cell lines as positive controls .

How should MGST2 antibodies be stored and handled?

Proper storage and handling of MGST2 antibodies is crucial for maintaining their activity and specificity:

• Storage temperature: Most MGST2 antibodies should be stored at -20°C

• Buffer composition: Typically supplied in PBS with 50% glycerol and 0.02% sodium azide at pH 7.2-7.4

• Aliquoting: Divide into small aliquots upon receipt to minimize freeze-thaw cycles

• Working dilution: Prepare immediately before use and store at 4°C for short-term (1-2 weeks)

• Shipping conditions: Usually shipped with cool packs or on wet ice

For long-term storage stability, avoid repeated freeze-thaw cycles as these can significantly reduce antibody activity. Most manufacturers recommend storing antibodies in their original buffer conditions rather than diluting for long-term storage .

How does the unique structure of MGST2 impact antibody selection and experimental design?

MGST2 possesses a distinct trimeric structure with unique catalytic properties that directly impact antibody selection strategies. Crystal structures reveal that MGST2 restricts catalysis to only one out of three active sites at a time through a concerted mechanism involving local unfolding coupled to global conformational changes .

When designing experiments:

• Epitope consideration: Select antibodies targeting epitopes that remain accessible in the membrane-bound conformation. The peptide region Y21-G71 has proven effective for antibody generation , while other manufacturers use peptides from amino acids 64-109 or regions within the internal domain.

• Conformational states: MGST2 undergoes substantial conformational changes when binding to GSH and during catalysis . The structure of apo-MGST2 shows structural heterogeneity, while the holo-MGST2 (with GSH) appears more rigid . Therefore:

  • For capturing all forms, target conserved regions outside the active site

  • For studying specific activation states, consider antibodies that preferentially recognize GSH-bound or substrate-free conformations

• Membrane extraction protocols: MGST2 is a multi-pass membrane protein localized to the endoplasmic reticulum and microsomal membranes . Extraction requires membrane-disrupting detergents that preserve the epitope structure while solubilizing the protein.

What are the optimal protocols for detecting MGST2 in different subcellular fractions?

MGST2 is primarily localized to the endoplasmic reticulum membrane and microsomal membrane as a multi-pass membrane protein . This localization presents unique challenges for detection:

Optimized Western Blot Protocol for MGST2 Detection:

• Sample preparation:

  • For total cell lysates: Use RIPA buffer supplemented with 1% digitonin or 0.5% DDM (n-dodecyl β-D-maltoside) to effectively solubilize membrane proteins

  • For subcellular fractionation: Isolate microsomes through differential centrifugation (10,000×g supernatant followed by 100,000×g pellet)

• Electrophoresis conditions:

  • Use 12-15% SDS-PAGE gels for optimal resolution of the ~17kDa MGST2 protein

  • Include positive controls such as U-937 or PC-12 cell lysates

• Transfer parameters:

  • Wet transfer at 30V overnight at 4°C for optimal transfer of hydrophobic membrane proteins

  • Use PVDF membrane (rather than nitrocellulose) for better retention of hydrophobic proteins

• Blocking and antibody incubation:

  • 5% non-fat milk in TBS-T (containing 0.1% Tween-20) for 1 hour at room temperature

  • Primary antibody dilution: 1:500 - 1:2000 in 1% BSA/TBS-T overnight at 4°C

  • Secondary antibody: HRP-conjugated anti-rabbit IgG at 1:5000 for 1 hour at room temperature

• Detection:

  • Enhanced chemiluminescence with extended exposure times (up to 5 minutes) may be required

How can researchers validate MGST2 antibody specificity and overcome cross-reactivity issues?

Thorough validation is essential for ensuring the reliability of MGST2 antibody data:

• Positive and negative tissue controls: Use tissues with known MGST2 expression patterns. Liver, spleen, skeletal muscle, heart, adrenals, pancreas, prostate, and testis show high expression, while lung, brain, placenta, and bone marrow have very low expression .

• Immunoabsorption studies: Pre-incubate the antibody with excess immunizing peptide. The specific signal should be significantly reduced or eliminated.

• Genetic validation methods:

  • Use MGST2 knockout/knockdown models (siRNA, CRISPR-Cas9) to confirm specificity

  • Overexpression of MGST2 should increase the signal proportionally

• Orthogonal validation: Compare results with alternative detection methods:

  • mRNA expression (RT-PCR or RNA-seq)

  • Mass spectrometry-based proteomics

  • Alternative antibodies targeting different epitopes

• Cross-reactivity assessment:

  • Test against recombinant MGST1 and MGST3, which share sequence homology

  • Use tissues from different species to evaluate cross-species reactivity

Multiple manufacturers claim their MGST2 antibodies undergo rigorous validation. For example, HPA010707 has been tested against protein arrays of 364 human recombinant protein fragments and IHC tissue arrays of 44 normal human tissues .

What are common challenges in detecting MGST2 and how can they be addressed?

Researchers often encounter several challenges when working with MGST2:

A specific consideration for MGST2 detection is its conformational heterogeneity. Crystal structures reveal that the apo-MGST2 shows structural heterogeneity, while the holo-MGST2 with GSH appears more rigid . This conformational flexibility may affect epitope accessibility in different experimental conditions.

How can MGST2 antibodies be used to investigate its role in oxidative stress and cell death pathways?

MGST2 plays a critical role in intracrine signaling of endoplasmic reticulum stress, oxidative DNA damage, and cell death . Advanced research applications include:

• Co-immunoprecipitation studies: Using MGST2 antibodies to identify protein interaction partners in the cell death pathway. Recommended protocol:

  • Cross-link cells with membrane-permeable crosslinkers (DSP)

  • Lyse in mild detergent buffer (1% digitonin)

  • Immunoprecipitate with MGST2 antibody

  • Analyze by mass spectrometry or Western blot for known pathway components

• Immunofluorescence co-localization: Investigate MGST2 redistribution during stress:

  • Double staining with ER markers (calnexin, PDI) to monitor ER localization

  • Co-staining with oxidative stress markers (8-oxo-dG) and cell death pathway components

• Proximity ligation assays (PLA): For detecting protein-protein interactions in situ:

  • Combine MGST2 antibody with antibodies against suspected interacting partners

  • Particularly useful for studying MGST2's interactions during LTC4 production

• ChIP-seq integration: Correlate MGST2 activity with transcriptional changes:

  • Immunoprecipitate MGST2 to identify associated chromatin regions

  • Compare with transcriptional profiles during oxidative stress

• Live-cell imaging: Using fluorescently tagged anti-MGST2 antibody fragments to track dynamics during stress responses

What methodological approaches can resolve discrepancies in MGST2 expression data?

Conflicting reports regarding MGST2 expression levels can arise from multiple factors. To resolve these discrepancies:

• Tissue-specific expression analysis:

  • Use antibodies validated specifically for the tissue of interest

  • Compare with RNA-seq or microarray data from the same tissue

  • Consider developmental stage and disease state influences on expression

• Single-cell analysis approaches:

  • Single-cell immunofluorescence with MGST2 antibodies

  • Flow cytometry to quantify MGST2 expression in heterogeneous cell populations

  • Single-cell RNA-seq correlation with protein-level data

• Quantitative Western blotting:

  • Include recombinant MGST2 protein standards at known concentrations

  • Use fluorescent secondary antibodies for more accurate quantification

  • Apply digital image analysis tools for precise band intensity measurement

• Standardized reporting:

  • Document complete antibody information (catalog number, lot, dilution, incubation conditions)

  • Report positive and negative controls used

  • Include validation evidence specific to the tissue or cell type studied

It's important to note that MGST2 expression varies significantly across tissues, with high expression in liver, spleen, skeletal muscle, heart, adrenals, pancreas, prostate, and testis, but very low expression in lung, brain, placenta, and bone marrow . This natural variation must be considered when interpreting experimental results.

How can MGST2 antibodies contribute to drug development targeting inflammatory pathways?

MGST2 is a potential therapeutic target for anti-inflammatory and anti-cancer drugs that interfere with prostaglandin and leukotriene biosynthesis . Research applications include:

• Target validation studies:

  • Use MGST2 antibodies to confirm target engagement by candidate compounds

  • Immunohistochemical analysis of MGST2 expression in disease tissues

  • Correlation of MGST2 levels with disease severity metrics

• High-throughput screening support:

  • Develop ELISA-based assays using MGST2 antibodies for compound screening

  • Immunofluorescence assays to monitor MGST2 localization changes upon drug treatment

• Mechanism of action studies:

  • Investigate how lead compounds affect MGST2 protein levels, localization, and interaction partners

  • Combine with activity assays to correlate structural changes with functional outcomes

• Translational biomarker development:

  • Design antibody-based assays to monitor MGST2 levels as pharmacodynamic biomarkers

  • Develop companion diagnostics for patient stratification based on MGST2 expression

Crystal structures of human MGST2 have revealed that it restricts catalysis to only one out of three active sites at a time through a concerted mechanism . This unique feature could be exploited for drug design, with MGST2 antibodies serving as valuable tools for validating the mechanism of novel inhibitors.

What emerging techniques are enhancing MGST2 antibody research precision?

Several cutting-edge approaches are improving the specificity and utility of MGST2 antibody applications:

• Super-resolution microscopy:

  • Techniques like STORM and PALM overcome diffraction limits to precisely localize MGST2 within membrane microdomains

  • Combined with MGST2 antibodies, enables nanoscale visualization of enzyme distribution and clustering

• Proximity labeling proteomics:

  • BioID or APEX2 fusions with MGST2 identify proximal proteins in living cells

  • Antibodies verify hits and validate the MGST2 interactome in different cellular states

• Automated image analysis algorithms:

  • Machine learning approaches improve quantification of MGST2 immunostaining patterns

  • Reduces inter-observer variability in tissue analysis

• Conformation-specific antibodies:

  • Development of antibodies that specifically recognize the catalytically active conformation

  • Enables tracking of MGST2 activation state rather than just protein levels

• Antibody engineering approaches:

  • Single-domain antibodies (nanobodies) against MGST2 for improved access to membrane-embedded epitopes

  • Site-specific conjugation strategies for precisely labeled detection reagents

These advanced techniques are particularly valuable given MGST2's membrane localization and complex structural dynamics that reveal synchronized conformational changes during catalysis .